We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A phase I study of combination chemotherapy with gemcitabine and oral UFT for advanced non-small cell lung cancer.
- Authors
Seto, T.; Yoh, K.; Asoh, H.; Yamamoto, H.; Semba, H.; Ichinose, Y.
- Abstract
A phase I study was carried out to determine the optimal dose and administration schedule for combined UFT plus gemcitabine therapy in patients with non-small cell lung cancer. Twenty-four patients (including 11 patients previously treated with cisplatin as the key drug) received oral UFT 400 mg x m(-2) on days 1 to 14 with intravenous infusions of gemcitabine (800 mg x m(-2) on days 8 and 15, or 900 mg x m(-2) on days 8 and 15, or 900 mg x m(-2) on days 1, 8 and 15). The most appropriate dosing option appeared to be 400 mg x m(-2) per day of oral UFT for 14 consecutive days with 900 mg x m(-2) gemcitabine on days 8 and 15. Eight of the 24 patients achieved partial response. The combination chemotherapy UFT and gemcitabine was well tolerated and may benefit patients with advanced non-small cell lung cancer. A multicentre phase II study using a 3-weekly regimen is in progress.
- Subjects
ANTIMETABOLITES; SMALL cell lung cancer; CANCER treatment
- Publication
British Journal of Cancer, 2002, Vol 86, Issue 11, p1701
- ISSN
0007-0920
- Publication type
journal article
- DOI
10.1038/sj.bjc.6600337